GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akari Therapeutics PLC (FRA:CLA) » Definitions » Shiller PE Ratio

Akari Therapeutics (FRA:CLA) Shiller PE Ratio : (As of Jun. 17, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Akari Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Akari Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Akari Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akari Therapeutics Shiller PE Ratio Chart

Akari Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Akari Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Akari Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Akari Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akari Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akari Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Akari Therapeutics's Shiller PE Ratio falls into.



Akari Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Akari Therapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Akari Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.761/131.7762*131.7762
=-0.761

Current CPI (Mar. 2024) = 131.7762.

Akari Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201312 0.000 98.326 0.000
201403 -57.840 99.695 -76.453
201406 -58.880 100.560 -77.158
201409 -4.720 100.428 -6.193
201412 -16.220 99.070 -21.575
201503 -3.696 99.621 -4.889
201506 -3.564 100.684 -4.665
201509 -106.920 100.392 -140.346
201512 36.720 99.792 48.489
201603 -4.553 100.470 -5.972
201606 -17.800 101.688 -23.067
201609 -0.633 101.861 -0.819
201612 -18.960 101.863 -24.528
201703 -18.700 102.862 -23.956
201706 -0.484 103.349 -0.617
201709 -16.780 104.136 -21.234
201712 -16.900 104.011 -21.411
201803 -1.423 105.290 -1.781
201806 -17.120 106.317 -21.220
201809 -4.029 106.507 -4.985
201812 -3.907 105.998 -4.857
201903 -2.850 107.251 -3.502
201906 -4.534 108.070 -5.529
201909 -2.364 108.329 -2.876
201912 -6.574 108.420 -7.990
202003 -2.694 108.902 -3.260
202006 -4.401 108.767 -5.332
202009 0.458 109.815 0.550
202012 -11.378 109.897 -13.643
202103 -2.549 111.754 -3.006
202106 -1.875 114.631 -2.155
202109 -0.531 115.734 -0.605
202112 -2.204 117.630 -2.469
202203 -1.754 121.301 -1.905
202206 -1.811 125.017 -1.909
202212 0.000 125.222 0.000
202303 0.247 127.348 0.256
202306 -0.877 128.729 -0.898
202312 0.000 129.419 0.000
202403 -0.761 131.776 -0.761

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Akari Therapeutics  (FRA:CLA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Akari Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Akari Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Akari Therapeutics (FRA:CLA) Business Description

Traded in Other Exchanges
Address
75/76 Wimpole Street, London, GBR, W1G 9RT
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. It operates mainly in United States and United Kingdom.

Akari Therapeutics (FRA:CLA) Headlines